Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04133909
Recruitment Status : Recruiting
First Posted : October 21, 2019
Last Update Posted : November 18, 2019
Sponsor:
Collaborator:
PPD
Information provided by (Responsible Party):
GlaxoSmithKline

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 13, 2023
Estimated Study Completion Date : January 13, 2023